Apollomics Inc. (NASDAQ: APLM) reported its full‑year 2025 financial results, marking the company’s first revenue of $8.5 million, all of which came from an upfront payment under a licensing agreement with LaunXP for vebreltinib in parts of Asia. The $8.5 million revenue represents a dramatic shift from zero revenue in 2024 and underscores the company’s new commercial traction.
The company’s net loss narrowed sharply to $10.9 million in 2025 from $53.9 million in 2024, a 79 % reduction driven largely by a 64 % cut in operating expenses. Research and development costs fell from $24.6 million to $5.5 million, while general and administrative expenses dropped from $17.8 million to $12.4 million. The cost‑control program, implemented by the new management team appointed in September 2025, has therefore translated into a substantially lower loss.
Cash and cash equivalents stood at $3.3 million at year‑end, down from $9.8 million in 2024, and the company’s equity position remains negative at $3.2 million. The liquidity squeeze signals that Apollomics will need additional financing to sustain its clinical program and regulatory milestones, even as the vebreltinib pipeline continues to progress.
Clinically, vebreltinib remains the company’s flagship asset. The Phase 2 program for non‑small‑cell lung cancer (NSCLC) with c‑MET amplification is advancing, and the company plans to file a U.S. Investigational New Drug application for accelerated approval in the first half of 2027. In China, vebreltinib has already received National Medical Products Administration approvals for three indications, including METex14‑skipping NSCLC, MET‑amplified NSCLC, and PTPRZ1‑MET fusion high‑grade gliomas.
Management emphasized that the company’s turnaround strategy hinges on disciplined spending and the commercialization of vebreltinib. CEO Hung‑wen (Howard) Chen stated, “Our primary focus is to advance the global development of vebreltinib for the treatment of patients with c‑MET alterations across different tumors.” He added that the company anticipates submitting the IND for accelerated approval in 2027, reflecting confidence in the drug’s clinical trajectory.
The financial results, while still a loss, signal a turning point for Apollomics. The first revenue stream, the sharp reduction in operating costs, and the continued regulatory progress together suggest that the company is moving from a cash‑burn phase toward a more sustainable operating model, albeit with limited liquidity that will require future capital raising.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.